For the quarter ending 2025-09-30, EXOZ had -$1,887,171 decrease in cash & cash equivalents over the period. -$1,870,018 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -2,286,991 | -4,216,707 |
| Accretion of deferred grant reimbursement | -13,055 | -27,158 |
| Depreciation of property and equipment | 71,603 | 142,759 |
| Non-cash lease expense | 23,235 | 14,629 |
| Tax payable | - | 0 |
| Stock-based compensation | 425,708 | 884,531 |
| Grants receivable | 45,236 | -479,875 |
| Prepaid expenses and other current assets | -88,699 | -76,371 |
| Accounts payable and accrued expenses | -26,276 | 6,377 |
| Due to related party | 11,431 | -32,209 |
| Tax receivable | 105,826 | - |
| Net cash provided by (used in) operating activities | -1,856,708 | -2,671,532 |
| Deferred grant reimbursement | 2 | 19,699 |
| Purchases of property and equipment | 13,310 | 81,619 |
| Net cash (used in) investing activities | -13,308 | -61,920 |
| Related party note | - | 0 |
| Deferred ipo cost | - | 0 |
| Payments on finance lease obligations | 17,155 | - |
| Net cash (used in) financing activities | -17,155 | 0 |
| Net increase (decrease) in cash, cash equivalents | -1,887,171 | -2,733,452 |
| Cash and cash equivalents at beginning of period | 9,719,310 | - |
| Cash and cash equivalents at end of period | 5,098,687 | - |
EXOZYMES INC. (EXOZ)
EXOZYMES INC. (EXOZ)